NCT04551885 2023-09-21
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
Fate Therapeutics
Fate Therapeutics
Genome & Company
Debiopharm International SA
Radboud University Medical Center
Pfizer